Mosunetuzumab IV (Lunsumio) and Mosunetuzumab SC (Lunsumio SC)

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses: Mosunetuzumab IV concentrate for solution for intravenous infusion 1 mg dose in a 2 mL vial containing 1 mL of liquid concentrate (1 mg/mL) 30 mg dose in a 50 mL vial containing 30 mL of liquid concentrate (1 mg/mL) Mosunetuzumab SC solution for subcutaneous injection 5 mg dose in a 2 mL vial containing 0.5 mL of solution (10 mg/mL) 45 mg dose in a 2 mL vial containing 1 mL of solution (45 mg/mL) Indication: Mosunetuzumab IV: As monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (grades 1 to 3a) who have received at least 2 prior lines of systemic therapy Mosunetuzumab SC: Same as mosunetuzumab IV